Reports Q3 revenue $103.693M, consensus $101.83M. “Our commercial momentum continues with over $100 million in sales this quarter and enables sustained investment in innovation. We are executing to plan – advancing three Phase 3 melanoma trials and multiple mid-stage programs – to deliver transformative outcomes for patients and sustained value for shareholders,” said Bahija Jallal, Chief Executive Officer of Immunocore (IMCR).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls
- Immunocore initiated with an Overweight at Wells Fargo
- Immunocore’s Innovative Approach: A New Hope for PRAME-Positive Cancer Treatment
- Immunocore’s Phase 3 Melanoma Study: A Potential Game Changer?
- Immunocore’s Promising Melanoma Study: A Potential Game-Changer